NO20003273D0 - Substituerte <beta>-alaniner - Google Patents

Substituerte <beta>-alaniner

Info

Publication number
NO20003273D0
NO20003273D0 NO20003273A NO20003273A NO20003273D0 NO 20003273 D0 NO20003273 D0 NO 20003273D0 NO 20003273 A NO20003273 A NO 20003273A NO 20003273 A NO20003273 A NO 20003273A NO 20003273 D0 NO20003273 D0 NO 20003273D0
Authority
NO
Norway
Prior art keywords
beta
compounds
prodrugs
halogen
hydrogen
Prior art date
Application number
NO20003273A
Other languages
English (en)
Norwegian (no)
Other versions
NO20003273L (no
Inventor
Peter Charles Astles
Neil Victor Harris
Andrew David Morley
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9727532.5A external-priority patent/GB9727532D0/en
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Publication of NO20003273L publication Critical patent/NO20003273L/no
Publication of NO20003273D0 publication Critical patent/NO20003273D0/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24Oxygen or sulfur atoms
    • C07D207/262-Pyrrolidones
    • C07D207/2632-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/272-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C275/00Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
    • C07C275/28Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C275/42Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Furan Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Pyrrole Compounds (AREA)
NO20003273A 1997-12-23 2000-06-22 Substituerte <beta>-alaniner NO20003273D0 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9727532.5A GB9727532D0 (en) 1997-12-23 1997-12-23 Chemical compounds
US9260298P 1998-07-13 1998-07-13
PCT/GB1998/003859 WO1999033789A1 (en) 1997-12-23 1998-12-23 SUBSTITUTED β-ALANINES

Publications (2)

Publication Number Publication Date
NO20003273L NO20003273L (no) 2000-06-22
NO20003273D0 true NO20003273D0 (no) 2000-06-22

Family

ID=26312873

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20003273A NO20003273D0 (no) 1997-12-23 2000-06-22 Substituerte <beta>-alaniner

Country Status (18)

Country Link
EP (1) EP1042279B1 (de)
JP (1) JP4555469B2 (de)
KR (1) KR20010033520A (de)
CN (1) CN1163477C (de)
AT (1) ATE289991T1 (de)
AU (1) AU747907B2 (de)
BR (1) BR9814376A (de)
CA (1) CA2316235A1 (de)
CZ (1) CZ20002342A3 (de)
DE (1) DE69829215T2 (de)
ES (1) ES2235383T3 (de)
HU (1) HUP0101701A3 (de)
IL (1) IL136584A (de)
NO (1) NO20003273D0 (de)
NZ (1) NZ505363A (de)
SK (1) SK9372000A3 (de)
TR (1) TR200001947T2 (de)
WO (1) WO1999033789A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010034317A (ko) * 1998-01-23 2001-04-25 한스 루돌프 하우스 Vla-4 길항제
ES2297943T3 (es) 1998-12-23 2008-05-01 Aventis Pharma Limited Dihidro-benzo(1,4)oxacinas y tetrahidroquinoxalinas.
KR100649819B1 (ko) * 1999-02-18 2007-02-28 에프. 호프만-라 로슈 아게 티오아미드 유도체
YU41202A (sh) * 1999-12-28 2005-03-15 Pfizer Products Inc. Ne-peptidni inhibitori vezivanja za ćeliju zavisnog od vla-4 korisni pri tretiranju inflamatornih, autoimunih i respiratornih bolesti
DE10019755A1 (de) * 2000-04-20 2001-11-08 Bayer Ag Neue Aminoaryl/cycloalkylcarbonsäuren als Integrinantagonisten
FR2812633A1 (fr) * 2000-08-04 2002-02-08 Aventis Cropscience Sa Derives de phenyl(thio)urees et phenyl(thio)carbamates fongicides
GB2369357A (en) * 2000-10-09 2002-05-29 Bayer Ag Aliphatic, cyclic amino carboxylic acids as integrin antagonists
GB2367816A (en) * 2000-10-09 2002-04-17 Bayer Ag Urea- and thiourea-containing derivatives of beta-amino acids
JP3786203B2 (ja) 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
JP4212358B2 (ja) 2000-12-28 2009-01-21 第一三共株式会社 Vla−4阻害薬
GB2377933A (en) 2001-07-06 2003-01-29 Bayer Ag Succinic acid derivatives useful as integrin antagonists
CA2528586A1 (en) 2003-07-24 2005-02-03 Daiichi Pharmaceutical Co., Ltd. Cyclohexanecarboxylic acid compound
JP2008539246A (ja) * 2005-04-28 2008-11-13 フェリング ベスローテン フェンノートシャップ Ibd治療のための新規化合物の使用
EP1961750B1 (de) 2005-12-13 2013-09-18 Daiichi Sankyo Company, Limited Vla-4-hemmendes arzneimittel
WO2008103378A2 (en) 2007-02-20 2008-08-28 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6306840B1 (en) * 1995-01-23 2001-10-23 Biogen, Inc. Cell adhesion inhibitors
IL123164A (en) * 1995-08-30 2001-03-19 Searle & Co Meta-guanidine urea thiourea or azacyclic amino benzoic acid derivatives and pharmaceutical compositions containing them
DE69710319T2 (de) * 1996-03-29 2002-08-14 G.D. SEARLE &amp; CO., CHICAGO Para-substituierte phenylpropansäure derivate als integrin-antagonisten
DE69706407T2 (de) * 1996-03-29 2002-05-29 G.D. Searle & Co., Chicago META-SUBSTITUIERTE PHENYLENDERIVATE UND IHRE VERWENDUNG ALS ALPHAvBETA3 INTERGRIN-ANTAGONISTEN ODER INHIBITOREN
PT1027328E (pt) * 1997-10-31 2006-11-30 Aventis Pharma Ltd Anilidas substituídas

Also Published As

Publication number Publication date
HK1034508A1 (en) 2001-10-26
ATE289991T1 (de) 2005-03-15
IL136584A (en) 2005-03-20
NO20003273L (no) 2000-06-22
TR200001947T2 (tr) 2001-01-22
DE69829215T2 (de) 2005-07-21
SK9372000A3 (en) 2002-03-05
EP1042279B1 (de) 2005-03-02
NZ505363A (en) 2005-02-25
CZ20002342A3 (cs) 2001-11-14
HUP0101701A3 (en) 2003-02-28
BR9814376A (pt) 2000-10-10
KR20010033520A (ko) 2001-04-25
CA2316235A1 (en) 1999-07-08
CN1163477C (zh) 2004-08-25
AU1771999A (en) 1999-07-19
HUP0101701A2 (hu) 2001-11-28
IL136584A0 (en) 2001-06-14
JP4555469B2 (ja) 2010-09-29
AU747907B2 (en) 2002-05-30
WO1999033789A1 (en) 1999-07-08
EP1042279A1 (de) 2000-10-11
DE69829215D1 (de) 2005-04-07
JP2001527061A (ja) 2001-12-25
ES2235383T3 (es) 2005-07-01
CN1283181A (zh) 2001-02-07

Similar Documents

Publication Publication Date Title
ATE289991T1 (de) Substituierte beta-alaninen
DK1027328T3 (da) Substituerede anilider
DE69523169D1 (de) Verwendung von Mangiferin oder seinen Derivaten zur kosmetischen Anwendung
TR200102959T2 (tr) İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
HUP0204496A2 (en) Novel piperidine compounds and pharmaceutical compositions containing the same and process for preparation the same
IT1295694B1 (it) Nitrossi derivati per la preparazione di medicamenti ad attivita antitrombinica
IL151172A0 (en) Amine derivatives, their preparation and use as bax modulators
ES2124545T3 (es) Azolidindionas como agentes antihiperglucemicos.
DE60012048D1 (de) Phenoxypropanolamin-derivate, ihre herstellung und therapeutische verwendung
CO4820432A1 (es) Composiciones farmaceuticas para el tratamiento de rinitis que comprenden acido 2-(4-(difenilmetil)-1-piperacinil)-ace- tico o amida derivada y un compuesto seleccionado de pseudoe fedrina,fenilpropanolamina y fenilefrina
EE9700282A (et) Bensimidasooli ühendid, nimetatud ühendeid sisaldavad farmatseutilised kompositsioonid ja nende kasutamine
ATE126221T1 (de) Thiazolidinverbindeungen, deren herstellung und therapeutische verwendung.
ATE165368T1 (de) Inhibitoren von testosteron-5-alpha reductase.
CO4410329A1 (es) Nuevos pirrolocarbazoles
NO944892L (no) N-substituerte 3-azabicyklo (3.2.0) hepatanderivater som neuroleptika osv.
DE69512208D1 (de) Aminosäurederivate und ihre verwendung als phospholipase-a2-inhibitoren
DE69402935D1 (de) Substituierte arylalkylaminobenzyl-aminopropanamide, ihre herstellung und verwendung als antiepileptische, neuroprotektive und antidepressive mittel
PT89082A (pt) Processo para a preparacao de novos derivados n-(23-vinblastinoilicos)do acido 1-amino-metilfosfonico
PT1068184E (pt) Derivados n-ariloxietilamina para o tratamento de depressao
EP0638564A4 (de) Benzothiazolsulfonamid-derivate, verfahren zu deren herstellung und anwendungen.
NO950177D0 (no) Farmakologisk aktive erivater
DE69816832D1 (de) Verwendung von 8-nitro-2,3,4,5-tetrahydro-1h-3-benzazepinen zur herstellung von pharmazeutischen zusammenstellungen zur behandlung von schlafstörungen
SE9603284D0 (sv) New compounds
TR200402493T4 (tr) Yeni 2,3-benzodiazepin türevleri ve aktif bileşen olarak bunları içeren farmasötik bileşimler.
BR9507668A (pt) Intermédio para preparar um composto farmaceuticamente atívo

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application